Our 2014 approach to breakthrough invasive fungal infections

Georg Maschmeyer, Thomas F. Patterson

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Summary: Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.

Original languageEnglish (US)
Pages (from-to)645-651
Number of pages7
JournalMycoses
Volume57
Issue number11
DOIs
StatePublished - Nov 1 2014

Keywords

  • Breakthrough fungal infection
  • Echinocandins
  • Fluconazole
  • Liposomal AmB
  • Posaconazole
  • Voriconazole

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Our 2014 approach to breakthrough invasive fungal infections'. Together they form a unique fingerprint.

Cite this